Literature DB >> 18212620

Six consecutive cases of successful adult ABO-incompatible living donor liver transplantation: a proposal for grading the severity of antibody-mediated rejection.

Daisuke Morioka1, Shinji Togo, Takafumi Kumamoto, Kazuhisa Takeda, Ken-ichi Matsuo, Yoshiaki Inayama, Shoji Yamanaka, Kuniya Tanaka, Itaru Endo, Jiro Maegawa, Hiroshi Shimada.   

Abstract

BACKGROUND: The clinical symptoms, histological findings, and treatments for antibody-mediated rejection (AMR), which is the leading cause of graft loss in adult ABO-incompatible liver transplantation (ABO-I-LT), have rarely been discussed.
METHODS: We performed adult living donor ABO-I-LT on six patients. We used anti-CD20 monoclonal antibody combined with plasma exchange preoperatively and intraportal or hepatic-arterial infusion, consisting of prostaglandin E1, corticosteroids, and protease inhibitor postoperatively to prevent AMR. Splenectomy was performed in patients 1, 4, 5 and 6 but not in patients 2 and 3. Weekly liver biopsies were performed after ABO-I-LT. When severe AMR was diagnosed, we performed plasma exchange combined with gamma-globulin bolus infusion (PE+IVIG).
RESULTS: In patients 1-3, severe jaundice, rapid decreases in platelet counts, and severe coagulopathy were observed in the early postoperative period. Liver biopsies sampled after the onset of these clinical findings were characterized by severe periportal and lobular hemorrhagic and neutrophil infiltration, suggesting that severe AMR occurred. However, after the initiation of PE+IVIG, AMR was remedied in all three patients. In patients 4-6, severe AMR was not observed. Mild AMR characterized by mild portal hemorrhagic infiltration was observed in patient 4, and moderate AMR characterized by moderate periportal and lobular hemorrhagic infiltration was observed in patient 6. Patients 4-6 did not require PE+IVIG and their clinical course was uneventful.
CONCLUSION: Given the experience of these six patients, we consider that AMR may be graded based on liver biopsy findings including hemorrhagic infiltration and neutrophil infiltration, as well as clinical findings. All six patients are currently doing well.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18212620     DOI: 10.1097/TP.0b013e31815e9672

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  6 in total

Review 1.  Cutaneous manifestations of common liver diseases.

Authors:  Sunil Dogra; Rashmi Jindal
Journal:  J Clin Exp Hepatol       Date:  2012-01-02

Review 2.  Management of ABO-incompatible living-donor liver transplantation: past and present trends.

Authors:  Vikram Raut; Shinji Uemoto
Journal:  Surg Today       Date:  2011-02-23       Impact factor: 2.549

3.  Bortezomib for acute antibody-mediated rejection in liver transplantation.

Authors:  F Paterno; M Shiller; G Tillery; J G O'Leary; B Susskind; J Trotter; G B Klintmalm
Journal:  Am J Transplant       Date:  2012-06-08       Impact factor: 8.086

4.  ABO-incompatible living donor liver transplantation without graft local infusion and splenectomy.

Authors:  Seung Duk Lee; Seong Hoon Kim; Sun-Young Kong; Young-Kyu Kim; Soon-Ae Lee; Sang-Jae Park
Journal:  HPB (Oxford)       Date:  2014-01-28       Impact factor: 3.647

5.  Plasma exchange in small intestinal transplantation between ABO-incompatible individuals: A case report.

Authors:  Qiuhui Zhang; Xingbin Hu; Aijun Xia; Jing Yi; Qunxing An; Xianqing Zhang
Journal:  Biomed Rep       Date:  2013-09-27

Review 6.  Current techniques for AB0-incompatible living donor liver transplantation.

Authors:  Silke Rummler; Astrid Bauschke; Erik Bärthel; Heike Jütte; Katrin Maier; Patrice Ziehm; Christina Malessa; Utz Settmacher
Journal:  World J Transplant       Date:  2016-09-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.